vTv Therapeutics Inc. Overview
Pro stress-test →vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates for diabetes and other chronic diseases, with its clinical pipeline led by cadisegliatin, currently in Phase 3 trial as a potential first-in-class oral glucokinase activator for type 1 diabetes treatment. The company is advancing toward a pivotal inflection point with topline data from the CATT1 Phase 3 trial expected in the second half of 2026.
Strategic Profile
Pro stress-test →vTv Therapeutics is a subsidiary of MacAndrews & Forbes Incorporated, providing strategic backing. The company has license agreements with multiple partners including Reneo Pharmaceuticals, Anteris Bio, Cantex Pharmaceuticals, and Novo Nordisk, enabling a diversified pipeline approach across metabolic, inflammatory, and oncology indications.
Competitive Landscape
Pro stress-test →vTv competes in the biopharmaceutical space developing oral small molecules for diabetes and chronic diseases. The company faces competition from established diabetes therapeutic developers and other clinical-stage biotech firms pursuing similar metabolic disease targets, but cadisegliatin's first-in-class positioning and FDA breakthrough designation provide competitive advantages if Phase 3 succeeds.
Industry Context
vTv Therapeutics Inc. operates in Biopharmaceutical / Clinical-Stage Drug Development.
Key facts
Founded: 2015 · Headquarters: High Point, North Carolina, US · Employees: 11-50 · Revenue: $17K · Market cap: $100M